Annexon Biosciences Revenue

Biotechnology Research • South San Francisco, California, United States • 101-200 Employees

Annexon Biosciences revenue & valuation

Annual revenue	$20,000,000
Revenue per employee	$170,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$64,000,000
Total funding	$380,000,000

Key Contacts at Annexon Biosciences

Bj Jones

Member, Board Of Directors

Bismay Mishra

Senior Director, Commercial Insights

Edmund Chang

Director, Clinical Biomarkers

Jennifer Mcalpine

Executive Director, Porfolio Strategy And Operations

Adrian Johnson

Senior Director, Global Drug Safety & Pharmacovigilance

Xavier Thompson

Senior Director, Ophthalmology, Medical Affairs

Sibel Boreham

Director Of Regulatory Affairs

Violet Torneros

Exec. Director, People Operations

Samarth Virk

Senior Director, Digital Marketing

Rahul Chhokar

Senior Field Medical Director

Company overview

Headquarters	180 Kimball Way, Suite 200, South San Francisco, California 94080, US
Phone number	+16508225500
Website	annexonbio.com
NAICS	541714
SIC	283
Keywords	Ophthalmology, Autoimmune, Neurodegeneration
Founded	2011
Employees	101-200
Socials

Annexon Biosciences Email Formats

Annexon Biosciences uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@annexonbio.com), used 83.8% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@annexonbio.com	83.8%
{last name}{last name}	doedoe@annexonbio.com	8.8%
{first name}{last name}	johndoe@annexonbio.com	7.4%

About Annexon Biosciences

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.

Employees by Management Level

Total employees: 101-200

Seniority

Employees

Director

Vice President

Entry

Employees by Department

Annexon Biosciences has 66 employees across 10 departments.

Departments

Number of employees

Funding Data

Explore Annexon Biosciences's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2022-08-08	14	$130,000,000
2024-01-20	14	$125,000,000
2024-07-05	14	$125,000,000

Funding Insights

$380,000,000

Total funding amount

$125,000,000

Most recent funding amount

Number of funding rounds

Annexon Biosciences Tech Stack

Discover the technologies and tools that power Annexon Biosciences's digital infrastructure, from frameworks to analytics platforms.

MediaElement.js

Video players

mOxie

JavaScript libraries

Underscore.js

JavaScript libraries

PhotoSwipe

JavaScript libraries

jQuery UI

JavaScript libraries

Chart.js

JavaScript graphics

jQuery Migrate

JavaScript libraries

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

PHP

Programming languages

WordPress

Blogs

Google Analytics

Analytics

Frequently asked questions

Annexon Biosciences is located in South San Francisco, California, US.

You can reach Annexon Biosciences at +16508225500.

Annexon Biosciences generates an estimated annual revenue of $20,000,000. This revenue figure reflects the company's market position and business performance in its industry.

Annexon Biosciences has an estimated valuation of $64,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Annexon Biosciences was founded in 2011, making it 15 years old. The company has established itself as a significant player in its industry over this time.

Annexon Biosciences has approximately 101-200 employees. The company continues to grow its workforce to support its business operations and expansion.

Annexon Biosciences has raised a total of $380,000,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Annexon Biosciences

Bj Jones

Member, Board Of Directors

Bismay Mishra

Senior Director, Commercial Insights

Edmund Chang

Director, Clinical Biomarkers

Jennifer Mcalpine

Executive Director, Porfolio Strategy And Operations

Adrian Johnson

Senior Director, Global Drug Safety & Pharmacovigilance

Xavier Thompson